CBD and epilepsy: promise tempered by safety and evidence gaps
Cannabidiol and epilepsy: therapeutic, mechanistic and clinical significance.
AI Summary
Epilepsy affects approximately 50 million people worldwide, and nearly 30% of patients have drug-resistant seizures despite treatment with multiple anti-epileptic medicines. This review examines cannabidiol (CBD) as a possible add-on treatment, exploring how it may influence neurotransmitters, ion channels, and neuroinflammatory pathways. It also gives particular attention to the potentially important—but conflicting—roles of the GPR55 and TRPV1 pathways.
The review concludes that emerging evidence supports CBD for certain severe, treatment-resistant epilepsies, but that its broader use remains limited by gaps in standardized research. CBD can affect the metabolism of other anti-epileptic drugs by inhibiting CYP2C19 and CYP3A4, creating potential safety concerns and making individualized dosing and careful monitoring important. The abstract does not report new quantitative treatment results; instead, it calls for stronger evidence, clearer clinical protocols, and better understanding of long-term safety and drug interactions.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.